Skip to content

Trial Summary

A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC MultiKinase Inhibitor (MKI) therapy.

Acronym:

AcceleRET-MTC

ACTRN/NCT /ethics:

NCT04760288

Scientific title:

A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer.

Sponsor / Cooperative group:

Hoffmann-La Roche

Trial & Patient Characteristics

Cancer TypeOther
Trial TypeTreatment
PhasePhase III
Age Range12 years and older
SexAll
Tumour Stream Thyroid
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2022-07-01
Anticipated End Date2028-04-15

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Emailsue.yeend@icon.team
Phone08 8292 2204
Principal InvestigatorDr Gonzalo Tapia Rico
Recruitment StatusNot Yet Recruiting